BACKGROUND Immunotherapies that target the interaction of programmed death 1 (PD-1)
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …

Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of
the disease differ widely across the globe depending on access to early detection and …

Background Pembrolizumab prolongs progression-free and overall survival among patients
with advanced melanoma and recurrence-free survival in resected stage III disease …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Summary Background The European Organisation for Research and Treatment of Cancer
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …

This ESMO Clinical Practice Guidelines provide updated recommendations on management
of cutaneous melanoma (diagnosis, treatment and follow-up), compiled by a …

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with
resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 …

Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is
associated with enhanced survival and antigen-specific T cell responses compared with …

The incidence of primary cutaneous melanoma continues to increase each year. Melanoma
accounts for the majority of skin cancer–related deaths, but treatment is usually curative …

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes
90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the …